Published : Oct-2021
No. of Pages : 54
1 Hemophilia A and B: Executive Summary
1.1 Catalyst
1.2 Related Reports
1.3 Upcoming Reports
2 Epidemiology
2.1 Disease Background
2.2 Risk Factors and Comorbidities
2.3 Global and Historical Trends
2.4 8MM Forecast Methodology
2.4.1 Sources
2.4.2 Sources Not Used
2.4.3 Forecast Assumptions and Methods
2.4.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
2.4.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
2.4.6 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Inhibitor Status
2.4.7 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
2.4.8 Types of Treatment Among Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
2.4.9 Diagnosed Prevalent Cases of Acquired Hemophilia
2.5 Epidemiological Forecast for Hemophilia A (2020-2030)
2.5.1 Diagnosed Prevalent Cases of Hemophilia A
2.5.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A
2.5.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A
2.5.4 Diagnosed Prevalent Cases of Hemophilia A by Severity
2.5.5 Diagnosed Prevalent Cases of Hemophilia A with Inhibitors
2.6 Epidemiological Forecast for Hemophilia B (2020-2030)
2.6.1 Diagnosed Prevalent Cases of Hemophilia B
2.6.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia B
2.6.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia B
2.6.4 Diagnosed Prevalent Cases of Hemophilia B by Severity
2.6.5 Diagnosed Prevalent Cases of Hemophilia B with Inhibitors
2.7 Epidemiological Forecast for Hemophilia A and Hemophilia B (2020-2030)
2.7.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
2.7.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
2.7.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
2.7.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
2.7.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors
2.7.6 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
2.7.7 Types of Treatment Among the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
2.7.8 Diagnosed Prevalent Cases of Acquired Hemophilia
2.8 Discussion
2.8.1 Epidemiological Forecast Insight
2.8.2 COVID-19 Impact
2.8.3 Limitations of the Analysis
2.8.4 Strengths of the Analysis
3 Appendix
3.1 Bibliography
3.2 About the Authors
3.2.1 Epidemiologist
3.2.2 Reviewers
3.2.3 Global Director of Therapy Analysis and Epidemiology
3.2.4 Global Head and EVP of Healthcare Operations and Strategy
Contact Us
List of Tables
Table 1: Summary of Newly Added Data Types
Table 2: Summary of Updated Data Types
Table 3: Relationship of Bleeding Severity with Clotting Factor Level.
Table 4: Comorbidities for Hemophilia
List of Figures
Figure 1: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, N, All Ages, 2020 and 2030
Figure 2: 8MM, Diagnosed Prevalent Cases of Acquired Hemophilia, Both Sexes, N, All Ages, 2020 and 2030
Figure 3: 8MM, Diagnosed Prevalence of Hemophilia A (%), Both Sexes, All Ages
Figure 4: 8MM, Diagnosed Prevalence of Hemophilia B (%), Both Sexes, All Ages
Figure 5: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
Figure 6: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Severity
Figure 7: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Inhibitors
Figure 8: 8MM, Sources Used to Forecast the Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
Figure 9: 8MM, Sources Used to Forecast the Types of Treatment Among Hemophilia A and Hemophilia B Patients
Figure 10: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Acquired Hemophilia
Figure 11: 8MM, Diagnosed Prevalent Cases of Hemophilia A, N, Both Sexes, All Ages, 2020
Figure 12: 8MM, Diagnosed Prevalent Cases of Hemophilia A by Age, N, Both Sexes
Figure 13: 8MM, Diagnosed Prevalent Cases of Hemophilia A by Sex, N, All Ages, 2020
Figure 14: 8MM, Diagnosed Prevalent Cases of Hemophilia A by Severity, N, Both Sexes, All Ages, 2020
Figure 15: 8MM, Diagnosed Prevalent Cases of Hemophilia A with Inhibitors, N, Both Sexes, All Ages, 2020
Figure 16: 8MM, Diagnosed Prevalent Cases of Hemophilia B, N, Both Sexes, All Ages, 2020
Figure 17: 8MM, Diagnosed Prevalent Cases of Hemophilia B by Age, N, Both Sexes
Figure 18: 8MM, Diagnosed Prevalent Cases of Hemophilia B by Sex, N, All Ages, 2020
Figure 19: 8MM, Diagnosed Prevalent Cases of Hemophilia B by Severity, N, Both Sexes, All Ages, 2020
Figure 20: 8MM, Diagnosed Prevalent Cases of Hemophilia B with Inhibitors, N, Both Sexes, All Ages, 2020
Figure 21: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, N, Both Sexes, All Ages, 2020
Figure 22: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Age, N, Both Sexes, 2020
Figure 23: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Sex, N, All Ages, 2020
Figure 24: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity, N, Both Sexes, All Ages, 2020
Figure 25: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors, N, Both Sexes, All Ages, 2020
Figure 26: 8MM, Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2020
Figure 27: 8MM, Types of Treatment Among the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2020
Figure 28: 8MM, Diagnosed Prevalent Cases of Acquired Hemophilia, N, Both Sexes, All Ages, 2020
